M.D. Anderson Cancer Center
The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients. The safety of this drug combination will also be studied.
Primary Objectives: Patients receive nivolumab intravenously (IV) over 30 minutes, doxorubicin IV over 15 minutes, vinblastine IV over 15 minutes, and dacarbazine IV over 60 minutes on days 1 and 15 of each cycle. I. To characterize the clinical preliminary efficacy of nivolumab plus AVD in pediatric, adolescent, and young adult patients with newly diagnosed early-stage non-bulky classical Hodgkin lymphoma based upon the overall response rate (ORR). II. To assess the safety of nivolumab plus AVD in pediatric, adolescent, and young adult patients with newly diagnosed early-stage non-bulky cl…
Inclusion Criteria: 1. Age ≥ 2 year to 21 years 2. Newly diagnosed early-stage (I/II) non-bulky (\<10cm) classical Hodgkin lymphoma 3. Baseline ejection fraction must be \> 40% 4. Adequate hepatic function (direct bilirubin \< 1.5x upper limit of normal (ULN) unless increase is due to Gilbert's disease or lymphoma involvement, and AST and/or ALT \< 3x ULN unless considered due to lymphoma involvement, in which case direct bilirubin \< 3x ULN or AST and/or ALT \< 5x ULN will be considered eligible) 5. Adequate renal function (creatinine clearance ≥ 30 mL/min) unless related to disease 6. ECOG…
Given by IV
Given by IV
Given by IV
Given by IV
Arctuva estimate
Verify or correct the compensation shown for this listing.